Glaxo Group Limited

Smithkline Beecham Corporation

Glaxosmithkline Intellectual Property Development Limited

Spero Therapeutics, Inc.

Stephen Frederick Moss

David Richard Witty

Christopher Norbert Johnson

Mervyn Thompson

Gregor James MacDonald

Mahmood Ahmed

Charles Edward Wade

Martin C Jones

Steven Mark Bromidge

Neil David Pearson

Qi Jin

Timothy James Miles

Haifeng Cui

Alan Hennessy

Antoinette Wilson

George Burton

Eric Hunt

Steven Coulton

David Witty

Harshad Kantilal Rami

Jeremy David Hinks

Steven Boakes

Esther Duperchy

Pamela Brown

Michael Dawson

Mona Simonovic

Stephen Christopher Martin Fell

Alfred John Eglington

Steven James Stanway

Gregor James Macdonald

The present invention provides a compound of formula (I), and its use in methods of treatment, including the treatment of bacterial infections. Methods for the preparation of the compound of formula (I) are also provided. The compound of formula (I) has the structure shown below, where —Rand —Rare each together with the carbonyl group and nitrogen alpha to the carbon to which it is attached an amino acid residue, except that R6 together with the carbonyl group and nitrogen alpha to the carbon to which it is attached is not a phenylalanine, leucine or valine residue and/or —Rtogether with the carbonyl group and nitrogen alpha to the carbon to which it is attached is not a leucine, iso-leucine, phenylalanine, threonine, valine or nor-valine residue, and -T, -A, -A, -Aand —Rare as discussed in the application:

Polymyxin compounds and uses thereof

The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions and treatment methods or uses as antibacterials for bacterial infections.

Compounds for use in antibacterial applications

Disclosed are quinoline compounds having affinity for the 5-HTreceptor and having the formula: where R, R, R, R, R, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.

[object Object]

Quinoline derivatives and their use as 5-HT6 ligands

The present invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.

Compounds of formula (I): or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein: P, P', R, R, n, p, q, r, and s are as defined in the specification, processes for preparing such compounds, pharmaceutical compositions comprising such compounds and their use in therapy.

Heterocyclic urea derivatives for the treatment of pain

Disclosed are novel quinoline compounds of formula (I), processes for their preparation, compositions containing them and their use in the treatment of CNS disorders. 

Quinoline derivatives and their use as 5-ht6 ligands

Disclosed are quinoline compounds of formula (I) having pharmacological activity, processes for their preparation, compositions containing them, and methods for the treatment of CNS and other disorders. 

Piperazinyl-quinoline derivatives useful for the treatment of CNS disorders

A compound of formula (I):whereinRis hydrogen, optionally substituted (C)alkyl or optionally substituted aryl;Ris hydrogen, optionally substituted (C)alkyl or optionally substituted aryl; orRand Rtogether form an optionally substituted 5 or 6 membered heterocyclic ring with or without additional heteroatoms;Ris (C)alkyl which is unsubstituted or substituted by fluoro, a hydroxy group which is optionally protected by a removable hydroxy protecting group, or by an amino group which is optionally protected by a removable amino protecting group;Ris hydrogen or methyl; and&#x2014;CORis carboxy or a carboxylate anion or the group Ris a removable carboxy protecting group. This invention also relates to processes for its preparation, intermediates and pharmaceutical compositions comprising compounds of formula (I). Compounds of formula (I) which include pharmaceutically acceptable salts or pharmaceutically acceptable in vivo hydrolysable esters thereof have a broad spectrum of anti-bacterial activity and show good stability towards DHP-1.

2-(pyrazol-3-yl)carbapenem derivatives

The invention relates to novel tetrahydroquinoline compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of various CNS disorders.

Isoquinoline derivatives useful in the treatment of CNS disorders

Compounds

The invention relates to novel compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.

Growing community of inventors

Harlow, United Kingdom

Stephen Frederick Moss